Shield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO - STXS News | RalliesShield Therapeutics Says On Track For Profitability In 2026; Appoints Michael Jensen As CFO
S
STXS• Q2 and H1 2026 trading update
- Shield Therapeutics PLC: Q2 and H1 2026 trading update
- Shield Therapeutics PLC: on track for profitability in 2026
- Shield Therapeutics PLC: appointment of Michael Jensen as chief financial officer
- Shield Therapeutics PLC: H1 revenues of $30.4 million with 21% growth in prescriptions
•
